Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid tree pollen subcutaneous immunotherapy in allergic rhinitis/rhinoconjunctivitis with or without asthma
2006-003067-31Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Aug 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Depigoid Bäume Mix in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by LETI Pharma. Primary endpoint: Symptom load over pollen season. Started Aug 2006; status: completed.
02
Drugs
Depigoid Bäume Mix
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2006-003067-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003067-31.